国产注射用重组人尿激酶原治疗急性心肌梗死疗效观察

目的：观察国产注射用重组人尿激酶原(rhPro-UK)治疗急性心肌梗死(AMl)的效果和副作用。方法：将31例发病6h内的AMl患者随机分为rhPro-UK组(n=16)和尿激酶(UK)组(n=15)。rhPro-UK组取rhPro-UK20mg溶于10ml生理盐水中3min内静脉注射，另取20mg溶于90ml生理盐水中30min内静脉滴注完毕。尿激酶组取UK150万单位溶于100ml生理盐水中30min内静脉滴注完毕。在溶栓90min时进行选择性冠状动脉造影，评价梗死相关动脉开通情况。评价出血并发症以及生化指标变化情况。结果：rhPro-UK组总的梗死相关动脉开通率为74．9％，UK组为66．7％(P=0．041)。rhPro-UK组无颅内出血，UK组有1例致命性颅内出血；其余出血并发症以及生化指标变化情况2组差异无统计学意义。结论：AMI时应用国产rhPro-UK进行静脉溶栓成功率高，使用安全，副作用低。

Therapeutic effect of recombinant prourokinase on the patients with acute myocardial infarction

Aim: To investigate the therapeutic effect and side effect of recombinant prourokinase (rhPro-UK) on the patients with acute myocardial infarction. Methods: A total of 31 cases of acute myocardial infarction treated by thrombolytic agents within 6 hours after onset were divided randomly into rhPro-UK group(n=16) and urokinase (UK) group(n=15). In rhPro-UK group, 20 mg rhPro-UK was used by intravenous injection within 3 minutes, then 20mg rhPro-UK was injected into vein within 30 minutes. In UK group, 1.5 million units UK was used by intravenous injection within 30 minutes. The dilation of infarct-related coronary artery was evaluated by coronary angiography. Results: The dilation rates were 74.9% in rhPro-UK group and 66.7% in UK group,respectively(P=0.041). There was no intracranial hemorrhage in rhPro-UK group. However in UK group, one patient experienced intracranial hemorrhage. Conclusion: rhPro-UK is safe and effective for the patients with acute myocardial infarction.